Clinical Study of Sogunjung-tang Granules in 30 Cases of Heartburn

이, 다은; 장, 혜연; 이, 유림; 이, 영수

doi:10.22246/jikm.2019.40.6.1193

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PP also undergoes plastic deformation which contributes to impact energy absorption. The matrix deformation occurs either through homogenous deformation of the matrix or from localized deformation around fiber ends .…”

Section: Resultsmentioning

confidence: 99%

Impact energy absorption of flax fiber‐reinforced polypropylene composites

2017

View full text Add to dashboard Cite

This work investigates the effects of fiber content and fiber orientation on the impact behavior of flax fiber‐reinforced polypropylene (PP) composites. The laminates of various fiber contents were manufactured by a vacuum bagging process; their impact properties were then measured using Charpy (i.e., in‐plane impact load) and drop weight (i.e., out‐of‐plane impact load) impact tests. Experiments were conducted on a range of samples with different fiber volume fractions and orientations. The results show significant variations in energy absorption according to the variations in fiber orientation. Composites with differing fiber orientations exhibit different energy absorption for the in‐plane and out‐of‐plane impact loads. The maximum Charpy energy absorption is obtained for the case of 0° fiber orientation, with the energy absorption generally lying in the range of 25–171 J/m. For the out‐of‐plane impact, the composites containing 30° fiber orientation absorb the highest amount of impact energy, and they can offer a better impact resistance in terms of higher peak force. The energy absorption generally lies in the range of 20–32 J. It was found that the energy absorption increases with increasing fiber content in the former (i.e., in‐plane impact load) and decreases in the latter (i.e., out‐of‐plane impact load). Fiber orientations influence the crack propagation and failure mode of the composites. The outcomes from this study indicate that flax fiber‐reinforced composite could be a commercially viable material for lightweight, crashworthy, and impact‐critical structures. POLYM. COMPOS., 39:4165–4175, 2018. © 2017 Society of Plastics Engineers

show abstract

Section: Resultsmentioning

confidence: 99%

Impact energy absorption of flax fiber‐reinforced polypropylene composites

2017

View full text Add to dashboard Cite

show abstract

“…Previous randomized controlled trials of SGJT have significantly affected digestive diseases such as chronic atrophic gastritis, peptic ulcer, constipation-predominant irritable bowel syndrome, and there are only observational studies in other fields, including nocturnal enuresis and heartburn. [34][35][36][37] Previously, there have been severe studies for SGJT, but clinical trials using it for pain reduction have been scarce. Therefore, this study conducting a randomized controlled trial to assess the effectiveness and safety of SGJT for relieving neuropathic pain, will be highly meaningful.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of SIKD1977 in Combination with Standard Treatment for Postherpetic Neuralgia: Study Protocol for a Double Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Clinical Trial

Jo¹,

Kim²,

Sung³

et al. 2023

JPR

View full text Add to dashboard Cite

Postherpetic neuralgia (PHN) is the most common chronic complication of herpes zoster, associated with poor quality of life and increased patient and healthcare resource expenditure. This randomized controlled trial aims to evaluate the efficacy and safety of SIKD1977 (Sogeonjungtang) in combination with standard treatment and estimate an effective dose for treating PHN. Patients and Methods: This is a protocol for a randomized, placebo-controlled, double-blind, multicenter trial. A total of 90 eligible participants with PHN will be recruited from three hospitals and randomly allocated to high-dose group, low-dose group, or placebo group in a 1:1:1 ratio. The trial will involve a 6-week oral administration of SIKD1977/placebo, and a 1-week follow-up period. The primary outcome will be the weekly average change in average daily pain score (ADPS) from baseline to the end of treatment. The secondary outcomes will include the weekly average changes in ADPS from baseline to week 2, 4, and 7, differences in Short-Form McGill Pain Questionnaire, Visual analogue scale, 5-level EuroQol-5 dimensions, Patient Global Impression of Change, and consumption of rescue drugs. All adverse events will be assessed during the trial. Conclusion: This study will provide evidence for the efficacy and safety of SIKD1977, and an effective dose for PHN. Trial Registration: This protocol has been registered in the Clinical Research Information Service with the identification code KCT0007939.

show abstract